Critical Review: Climb Bio (CLYM) & Its Rivals

Climb Bio (NASDAQ:CLYM) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Climb Bio to similar businesses based on the strength of its risk, institutional ownership, profitability, dividends, earnings, analyst recommendations and valuation.

Profitability

This table compares Climb Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Insider and Institutional Ownership

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.2% of Climb Bio shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Climb Bio and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-0.92
Climb Bio Competitors	$9.58 billion	$147.39 million	-5.43

Climb Bio’s peers have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Climb Bio and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7772	21188	48893	1232	2.55

Climb Bio currently has a consensus price target of $10.00, suggesting a potential upside of 412.82%. As a group, “Pharmaceutical preparations” companies have a potential upside of 187.75%. Given Climb Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than its peers.

Volatility & Risk

Climb Bio has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Comparatively, Climb Bio’s peers have a beta of 3.71, indicating that their average stock price is 271% more volatile than the S&P 500.

Summary

Climb Bio beats its peers on 7 of the 13 factors compared.

Climb Bio Company Profile

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.